Genentech's Avastin Falls Short in Test as Colon Cancer Medicine


April 23, 2009

The New York Times

In results from a widely watched clinical trial, the drug Avastin failed to show a significant effect on preventing the recurrence of colon cancer, the drug’s maker, Genentech, said early Wednesday.

Although Avastin is already a best-selling cancer treatment, success in this trial could have paved the way to a new use of the drug, potentially increasing sales by billions of dollars a year... Read More